Navigation Links
Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference
Date:4/12/2012

RICHMOND, Calif., April 12, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 1:30 pm ET on Friday, April 20, 2012, at the Future Leaders in the Biotech Industry Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. It has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Parkinson's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo has entered into a strategic collaboration with Shire to develop therapeutics for hemophilia and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at the Sixth Annual JMP Securities Healthcare Conference
2. Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
3. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
4. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
5. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
9. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
10. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , May 6, 2016 Zymo Research Corporation will ... at the American Urological Association,s Annual Meeting, the largest ... and isolates total DNA from a large volume of urine ... the company,s booth #5151 at the San Diego ... Conditioning Buffer ™ (UCB ™ ) that preserves ...
(Date:5/6/2016)... May 6, 2016 ReportsnReports.com ... 2016" to its database. The report provides comprehensive ... of the products at various stages of development. ... pipeline product development. It also provides information about ... trial status, trial start and end dates, and, ...
(Date:5/6/2016)... that we now stock the ( most advanced surgical and microscopic camera ) currently available, ... the consumer market in March 2016. Photo - http://photos.prnewswire.com/prnh/20160505/364465 ... ... ... GP-UH532 camera is the newest iteration of Panasonic,s 1080p HD camera and is part of ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... ... This Mother’s Day kicks off the start of an important week not just ... takes place May 8-May 14. , Throughout the celebration, the U.S. Department of ... their health a top priority. Women everywhere are being encouraged to take steps toward ...
(Date:5/6/2016)... MOOREFIELD, W.V. (PRWEB) , ... May 06, 2016 , ... ... by WestBow Press) shares accounts of dying patients who have allowed those holding vigil ... June E. Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain ...
(Date:5/5/2016)... Aliso Viejo, CA (PRWEB) , ... May 05, 2016 , ... ... use in Final Cut Pro X. Drag and drop a TransWipe preset between two ... project. Choose from smooth corner wipes to colored panels with customizable color and orientation ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pivot ... the industry’s gold standard KLAS Performance Report, Epic Consulting 2016 - ... organizations that specialize in consulting services for electronic health record (EHR) solutions from ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is ... (RWS) for public stakeholder review. The stakeholder review is an important opportunity for interested ... goals and delivers value to the wool industry., The RWS is intended to be ...
Breaking Medicine News(10 mins):